A systematic review of the association between anti-β-2 glycoprotein I antibodies and APS manifestations

Jiang, Debbie; Lim, Wendy; Crowther, Mark; García, David

doi:10.1182/bloodadvances.2021005205

Cited by 21 publications

(20 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In most cases, the high-risk triple-positive profile is confirmed after 12 weeks, making it a reliable estimate for initial risk evaluation [158,160]. In a recent meta-analysis, no evidence was observed to assume that isolated IgG aβ2GPI can predict clinical APS manifestations, while it is often considered as the most pathogenic of all aPL [161]. Clinical relevance of single aCL positivity is doubtful, as this may represent presence of non-pathogenic antibodies, not directed to β2-glycoprotein I, but to cardiolipin itself [114].…”

Section: Antibody Profilesmentioning

confidence: 99%

“…Some authors suggested to perform aDI testing as second-line test in patients with single positivity for aβ2GPI or double positivity to identify pathogenic aβ2GPI [189,192]. Although isolated aβ2GPI might not be associated with thrombosis [161], aDI could possibly identify a pathogenic subtype. aDI is not routinely available in many laboratories as commercial assays are very limited, but if aDI testing is available, this approach seems appropriate.…”

Section: Anti-domain I β2-glycoprotein I Antibodiesmentioning

confidence: 99%

See 1 more Smart Citation

Laboratory Diagnosis of Antiphospholipid Syndrome: Insights and Hindrances

Vandevelde

Devreese

2022

JCM

View full text Add to dashboard Cite

Diagnosis of antiphospholipid syndrome (APS) requires the presence of a clinical criterion (thrombosis and/or pregnancy morbidity), combined with persistently circulating antiphospholipid antibodies (aPL). Currently, laboratory criteria aPL consist of lupus anticoagulant (LAC), anticardiolipin antibodies (aCL) IgG/IgM, and anti-β2 glycoprotein I antibodies (aβ2GPI) IgG/IgM. Diagnosis and risk stratification of APS are complex and efforts to standardize and optimize laboratory tests have been ongoing since the initial description of the syndrome. LAC detection is based on functional coagulation assays, while aCL and aβ2GPI are measured with immunological solid-phase assays. LAC assays are especially prone to interference by anticoagulation therapy, but strategies to circumvent this interference are promising. Alternative techniques such as thrombin generation for LAC detection and to estimate LAC pathogenicity have been suggested, but are not applicable yet in routine setting. For aCL and aβ2GPI, a lot of different assays and detection techniques such as enzyme-linked immunosorbent and chemiluminescent assays are available. Furthermore, a lack of universal calibrators or standards results in high variability between the different solid-phase assays. Other non-criteria aPL such as anti-domain I β2 glycoprotein I and antiphosphatidylserine/prothrombin antibodies have been suggested for risk stratification purposes in APS, while their added value to diagnostic criteria seems limited. In this review, we will describe laboratory assays for diagnostic and risk evaluation in APS, integrating applicable guidelines and classification criteria. Current insights and hindrances are addressed with respect to both laboratory and clinical implications.

show abstract

Section: Antibody Profilesmentioning

confidence: 99%

Section: Anti-domain I β2-glycoprotein I Antibodiesmentioning

confidence: 99%

Laboratory Diagnosis of Antiphospholipid Syndrome: Insights and Hindrances

Vandevelde

Devreese

2022

JCM

View full text Add to dashboard Cite

show abstract

“…22,23 Among these three aPL, LA has the strongest association with the arterial and venous thrombotic complications and pregnancy morbidity in adults. 22,23 Isolated positive β2GPI…”

Section: Discussionmentioning

confidence: 99%

All catastrophes are not catastrophic antiphospholipid syndrome

Singal

Kouides

2022

American J Hematol

View full text Add to dashboard Cite

“…Определение перечисленных аФЛ имеет значение не только для подтверждения диагноза АФС, но и для оценки риска рецидивирования тромбозов [7][8][9]. Для улучшения лабораторной диагностики АФС и стратификации риска развития тромбозов активно изучаются так называемые «некритериальные» аФЛ, к которым в первую очередь относятся антитела к домену I β 2 -гликопротеина 1 (антиβ 2 -ГП1DI) [10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25]. β 2 -гликопротеин 1 (β 2 -ГП1), или аполипопротеин Н, являющийся «кофактором» при определении аКЛ, состоит из 5 доменов [ 2 3-2 5].…”

Section: Discussionunclassified

Antibodies to domain I β2 -glycoprotein 1 in patients with antiphospholipid syndrome and systemic lupus erythematosus

Cheldieva

Reshetnyak

Черкасова³

et al. 2022

Naučno-praktičeskaâ revmatologiâ

View full text Add to dashboard Cite

The study of antiphospholipid antibodies (aPL), not included in the Sydney diagnostic criteria, in antiphospholipid syndrome (APS) and systemic lupus erythematosus (SLE) is poorly understood.The aim of this study – to determine the clinical significance of IgG antibody testing for domain I β2 -glycoprotein 1 (β2 -GP1DI) – IgG anti-β2 -GP1DI in patients with APS with and without SLE.Materials and methods. The study included 187 patients with APS with or without SLE, 49 patients formed a comparison group, and 100 relatively healthy individuals formed a control group. IgG/IgM antibodies to cardiolipin and IgG/ IgM anti-β2 -GP1 were determined by enzyme immunoassay (ELISA) in patients with or without APS, and IgG antiβ2 -GP1DI was determined by chemiluminescence assay in all patients and controls.Results. IgG anti-β2 -GP1DI was detected in 37 (71%) of 52 patients with primary APS (PAPS), in 6 (50%) of 12 patients with probable APS, in 42 (71%) of 59 patients with SLE+APS, in 17 (26%) of 64 patients with SLE, in 1 (2%) of comparison group and in none of control group. IgG anti-β2 -GP1DI was significantly associated with PAPS and SLE+APS compared with patients with SLE (p=0.0002 and p=0.0001, respectively). The association of IgG anti-β2 -GP1DI with clinical manifestations of APS (thrombosis (χ2 =9.69; p=0.001) and obstetric pathology (χ2 =4.19; p=0.04)) was detected. There was a significant association of IgG anti-β2 -GP1DI with arterial thrombosis (χ2 =8.84; p=0.002) and with late gestational obstetric pathology (χ2 =6.35; p=0.01). High specificity of IgG anti-β2 - GP1DI depending on the diagnosis and clinical manifestations of APS was noted despite low sensitivity: specificity for thrombosis was 84%, for obstetric pathology – 94%, for APS – 89%. Isolated IgG anti-β2 -GP1DI positivity was reported in 2% of 50 aPL negative patients and was not associated with APS manifestations.Conclusion. The frequency of IgG anti-β2 -GP1DI detection was higher in patients with APS compared to patients with SLE, comparison group and control (p<0.05). Positive IgG anti-β2 -GP1DI values were significantly associated with thrombotic complications and with obstetric pathology (χ2 =8.84; p=0.002 and χ2 =6.35; p=0.01). Specificity>˂ 0.05). Positive IgG anti-β2 -GP1DI values were significantly associated with thrombotic complications and with obstetric pathology (χ2 =8.84; p=0.002 and χ2 =6.35; p=0.01). Specificity of IgG anti-β2 -GP1DI for APS and its clinical manifestations (thrombosis and obstetric pathology) was higher than sensitivity: 89%, 94%, and 84%, respectively.

show abstract

A systematic review of the association between anti-β-2 glycoprotein I antibodies and APS manifestations

Cited by 21 publications

References 53 publications

Laboratory Diagnosis of Antiphospholipid Syndrome: Insights and Hindrances

Laboratory Diagnosis of Antiphospholipid Syndrome: Insights and Hindrances

All catastrophes are not catastrophic antiphospholipid syndrome

Antibodies to domain I β2 -glycoprotein 1 in patients with antiphospholipid syndrome and systemic lupus erythematosus

Contact Info

Product

Resources

About